The following articles, on various topics pertaining to work done by the Company, were published by some of Neurochem's employees, principal investigators, researchers and external collaborators. It also includes scientific abstracts presented at international scientific conferences by these researchers or other specialists.

The following articles were published by Neurochem's principal investigators and members of the research and development team, on various topics pertaining to research done by the Company.

  • Chakfe, Y., R. Seguin, J.P. Antel, C. Morissette, D. Malo,
    D. Henderson, and P. Seguela.
    "ADP and AMP induce interleukin-1ß release from microglial cells through activation of ATP-primed P2X7 receptor channels."
    J. Neurosci. 22 (2002): 3061-3069.

  • Chalifour R.J., R.W. McLaughlin, L. Lavoie, C. Morissette,
    N. Tremblay, M. Boulé, P. Sarazin, D. Stéa, D. Lacombe,
    and P. Tremblay.
    "Stereoselective interactions of peptide inhibitors with the ß-amyloid peptide." J. Biol. Chem. 278 (2003): 34874-34881.

  • Chalifour, R.J., L. Lavoie, C. Morissette, M. Boulé,
    R.W. McLaughlin, P. Sarazin, D. Stéa, and F. Gervais.
    Stereoselective peptide inhibitors of amyloid-ß (1-40) assembly.
    Eds. M. Bély and A. Apathy.
    Proc. IXth Int. Symp. Amyloidosis. David Apathy, Budapest (2001): 454-456.

  • Chishti, M.A., D.S. Yang, C. Janus, A.L. Phinney, P. Horne,
    J. Pearson, R. Strome, N. Zuker, J. Loukides, J. French,
    S. Turner, G. Lozza, M. Grilli, S. Kunicki, C. Morissette,
    J. Paquette, F. Gervais, C. Bergeron, P.E. Fraser, G.A. Carlson, P.S. George-Hyslop, and D. Westaway.
    "Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695."
    J. Biol. Chem. 276 (2001): 21562-21570.

  • Dudal, S., P. Krzywkovski, J. Paquette, C. Morissette,
    D. Lacombe, P. Tremblay, and F. Gervais.
    "Inflammation occurs early during Aß deposition process in TgCRND8 mice."
    Neurobiol. Aging (2004): In press.

  • Dudal, S., P. Krzywkowski, S. Kunicki, J. Paquette,
    and C. Morissette.
    Characterization of a model of hAPP transgenic mice: amyloid deposition and inflammation in the brain.
    Eds. M. Bély and A. Apathy.
    Proc. IXth Int. Symp. Amyloidosis. David Apathy, Budapest (2001): 457-459.

  • Dumery, L., F. Bourdel, Y. Soussan, A. Fialkowsky, S. Viale, P. Nicolas, and M. Reboud-Ravaux.
    "Beta-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's Disease."
    Pathol. Biol. 49 (2001): 72-85.

  • Garceau, D., C. Gurbindo, and J. Laurin.
    "Safety, tolerability and pharmacokinetic profile of Fibrillex™ (anti-AA amyloid agent) in healthy and renal impaired subjects."
    Eds. M. Bély and A. Apathy.
    Proc.IXth Int. Symp. Amyloidosis. David Apathy, Budapest (2001): 116-118.

  • Gervais, F., C. Morissette, and X. Kong.
    "Proteoglycans and amyloidogenic proteins in peripheral amyloidosis."
    Curr. Med. Chem. 3 (2003): In press.

  • Gervais, F., R. Chalifour, X. Kong, C. Morissette, J. Paquette.
    GAG mimetics: advance in multiple therapeutic areas.
    Eds. M. Bély and A. Apathy.
    Proc. IXth Int. Symp. Amyloidosis. David Apathy, Budapest (2001): 589-592.

  • Gervais, F.
    "Amyloid-Those deadly fibrils."
    Eur. Biopharm. Rev. Autumn (2001): 40-42.

  • Gervais, F., R. Chalifour, D. Garceau, X. Kong, J. Laurin,
    R. McLaughlin, C. Morissette, and J. Paquette.
    "Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy."
    Amyloid 8 Suppl. (2001): 28-35.

  • Huang, T.H., D.S. Yang, P.E. Fraser, and A. Chakrabartty.
    "Alternate Aggregation Pathways of the Alzheimer beta -Amyloid Peptide. An in-vitro model of preamyloid."
    J. Biol. Chem. 275 (2000): 36436-36440.

  • Huang, T.H., D.S. Yang, N.P. Plaskos, S. Go, C.M. Yip,
    P.E. Fraser, and A. Chakrabartty.
    "Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide."
    J. Mol. Biol. 297 (2000): 73-87.

  • Inoue, S., M. Kuroiwa, and R. Kisilevsky.
    "Basement membranes, microfibrils and beta amyloid fibrillogenesis in Alzheimer's Disease: high resolution ultrastructural findings."
    Brain Res. Rev. 29 (1999): 218-231.

  • Inoue, S., M. Kuroiwa, R. Tan, and R. Kisilevsky.
    "A high resolution ultrastructural comparison of isolated and in situ murine AA amyloid fibrils."
    Amyloid 5 (1998): 99-110.

  • Inoue, S., M. Kuroiwa, M.J. Saraiva, A. Guimaraes,
    and R. Kisilevsky.
    "Ultrastructure of familial amyloid polyneuropathy amyloid fibrils: examination with high-resolution electron microscopy."
    J. Struct. Biol. 124 (1998): 1-12.

  • Inoue, S., P.G. Hultin, W.A. Szarek, and R. Kisilevsky.
    "Effect of poly (Vinylsulfonate) on murine AA Amyloid: A high-resolution ultrastructural study."
    Lab. Invest. 74 (1996): 1081-1090.

  • Keane, M.P. and R.M. Strieter.
    "Chemokine signaling in inflammation."
    Crit. Care Med. 28 4 Suppl. (2000): N13-26.

  • Kisilevsky, R. and P.E. Fraser.
    "Aß amyloidogenesis: Unique, or variation on a systemic theme?"
    Critical Rev. Biochem. Mol. Biol. 32 (1997): 361-404.

  • Kisilevsky, R., L. Lemieux, L. Boudreau, D.S. Yang,
    and P.E. Fraser.
    "New clothes for amyloid enhancing factor (AEF): silk as AEF."
    Amyloid 6 (1999): 98-106.

  • Kisilevsky, R.
    "Can deposition of amyloid be prevented in Alzheimer's Disease?"
    Ann. N.Y. Acad. Sci. 856 (1997): 117-127.

  • Kisilevsky, R.
    "Anti-amyloid drugs: Potential in the treatment of diseases associated with aging."
    Drugs & Aging 8 (1996): 75-83.

  • Kisilevsky, R., L.J. Lemieux, P.E. Fraser, X. Kong, P.G. Hultin, and W.A. Szarek.
    "Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's Disease."
    Nat. Med. 1 (1995): 143-148.

  • Knight, J.L. and D.F. Weaver.
    "A computational quantitative structure-activity relationship study of carbamate anticonvulsants using quantum pharmacological methods."
    Seizure 7 (1998): 347-354.

  • McLaurin, J., T. Franklin, W.J. Kuhns, and P.E. Fraser.
    "A sulfated proteoglycan aggregation factor mediates amyloid-beta peptide fibril formation and neurotoxicity."
    Amyloid 6 (1999): 233-243.

  • McLaurin, J., T. Franklin, X. Zhang, J. Deng, and P.E. Fraser.
    "Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth."
    Eur. J. Biochem. 266 (1999): 1101-1110.

  • Morissette, C., V. Caouras, and F. Gervais.
    In vitro cytotoxicity assay for screening potential therapeutics for cerebral amyloid angiopathy disorder.
    Eds. M. Bély and A. Apathy.
    Proc.IXth Int. Symp. Amyloidosis. David Apathy, Budapest (2001) 451-453.

  • Tan, C. Y., D.S. Wainman, and D.F. Weaver.
    "N-, a-, and b-substituted 3-aminopropionic acids: design, syntheses and antiseizure activities."
    Bioorg. Med. Chem. 11 Jan 2003: 113-21.

  • Tan, C. Y., D.S. Wainman, and D.F. Weaver.
    "3-amino-3-arylpropionic acids: synthesis and antivonvulsant activities."
    Ph D. Thesis (2001): 1-18.

  • Tan, C. Y., A.J. Campbell, D.S. Wainman and D.F. Weaver.
    "b-alanine analogues: a novel class of anticonvulsant molecules."
    Ph. D. Thesis (2001): 1-21.

  • Yang, D.S., J. McLaurin, K. Qin, D. Westaway,
    and P.E. Fraser.
    "Examining the zinc binding site of the amyloid-beta peptide [In Process Citation]."
    Eur. J. Biochem. 267 (2000): 6692-6698.

  • Yang, D.S., C.M. Yip, T.H. Huang, A. Chakrabartty,
    and P.E. Fraser.
    "Manipulating the amyloid-beta aggregation pathway with chemical chaperones."
    J. Biol. Chem. 274 (1999): 32970-32974.

  • Zhang, Y., R. McLaughlin, C. Goodyer, and A. LeBlanc.
    "Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons."
    J. Cell. Biol. 156 (2002): 519-529.

Our site is best viewed with IE4+ at a resolution of 1024×768.
All contents copyright © 1998-2007 Neurochem Inc.
Terms, Conditions and Legal Notice.